342 related articles for article (PubMed ID: 25381822)
1. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
[TBL] [Abstract][Full Text] [Related]
2. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
3. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
[TBL] [Abstract][Full Text] [Related]
4. Angiomotin promotes breast cancer cell proliferation and invasion.
Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J
Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626
[TBL] [Abstract][Full Text] [Related]
5. Angiomotin promotes the malignant potential of colon cancer cells by activating the YAP-ERK/PI3K-AKT signaling pathway.
Zhang Y; Yuan J; Zhang X; Yan F; Huang M; Wang T; Zheng X; Zhang M
Oncol Rep; 2016 Dec; 36(6):3619-3626. PubMed ID: 27779692
[TBL] [Abstract][Full Text] [Related]
6. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.
Wang J; Wang H; Zhang Y; Zhen N; Zhang L; Qiao Y; Weng W; Liu X; Ma L; Xiao W; Yu W; Chu Q; Pan Q; Sun F
Cell Signal; 2014 May; 26(5):1048-59. PubMed ID: 24468535
[TBL] [Abstract][Full Text] [Related]
7. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
8. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.
Moleirinho S; Hoxha S; Mandati V; Curtale G; Troutman S; Ehmer U; Kissil JL
Elife; 2017 May; 6():. PubMed ID: 28464980
[TBL] [Abstract][Full Text] [Related]
9. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
[TBL] [Abstract][Full Text] [Related]
10. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
11. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
Hong W
Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
[TBL] [Abstract][Full Text] [Related]
12. Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.
Lv M; Li S; Luo C; Zhang X; Shen Y; Sui YX; Wang F; Wang X; Yang J; Liu P; Yang J
Oncotarget; 2016 Mar; 7(11):12393-403. PubMed ID: 26848622
[TBL] [Abstract][Full Text] [Related]
13. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
14. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract][Full Text] [Related]
15. AMOT is required for YAP function in high glucose induced liver malignancy.
Liu Y; Lu Z; Shi Y; Sun F
Biochem Biophys Res Commun; 2018 Jan; 495(1):1555-1561. PubMed ID: 29217192
[TBL] [Abstract][Full Text] [Related]
16. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
17. Modular mimicry and engagement of the Hippo pathway by Marburg virus VP40: Implications for filovirus biology and budding.
Han Z; Dash S; Sagum CA; Ruthel G; Jaladanki CK; Berry CT; Schwoerer MP; Harty NM; Freedman BD; Bedford MT; Fan H; Sidhu SS; Sudol M; Shtanko O; Harty RN
PLoS Pathog; 2020 Jan; 16(1):e1008231. PubMed ID: 31905227
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
Wang W; Li N; Li X; Tran MK; Han X; Chen J
Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
[TBL] [Abstract][Full Text] [Related]
19. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
Mooring M; Fowl BH; Lum SZC; Liu Y; Yao K; Softic S; Kirchner R; Bernstein A; Singhi AD; Jay DG; Kahn CR; Camargo FD; Yimlamai D
Hepatology; 2020 May; 71(5):1813-1830. PubMed ID: 31505040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
